Work

Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.9591

Authors: Rachel S Goodman, Aleigha Lawless, Rachel Woodford, Faisal Fa'ak, Asha Tipirneni, James Randall Patrinely, Hui-Ling Yeoh, Suthee Rapisuwon, Andrew Haydon, Iman Osman, Janice M. Mehnert, Georgina V. Long, Ryan J. Sullivan, Matteo S. Carlino, Alexander M. Menzies, Douglas Buckner Johnson

Institutions: Vanderbilt University, Massachusetts General Hospital, Melanoma Institute Australia, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Georgetown University Medical Center, Vanderbilt University Medical Center, Alfred Health, Georgetown Lombardi Comprehensive Cancer Center, The University of Sydney, Royal North Shore Hospital, Westmead Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Burroughs Wellcome Fund, National Institutes of Health

OpenAlex ID: W4379280926

Cites:

Cited by: 6

Related to: 10